Phase I, Open-label Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of SPH1188-11 Tablets for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
Phase of Trial: Phase I
Latest Information Update: 23 Aug 2017
At a glance
- Drugs SPH 1188-11 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Shanghai Pharmaceuticals Holding
- 16 Aug 2017 Status changed from not yet recruiting to recruiting.
- 03 Aug 2017 New trial record